Hematopoietic Stem Cell Transplantation in Thalassemia and Related Disorders
Author Information
Author(s): Emanuele Angelucci, Federica Pilo, Clara Targhetta, Martina Pettinau, Cristina Depau, Claudia Cogoni, Sara Usai, Mario Pani, Laura Dessì, Donatella Baronciani
Primary Institution: Ospedale Oncologico di Riferimento Regionale “Armando Businco” Cagliari
Hypothesis
The study investigates the effectiveness of allogeneic hemopoietic stem cell transplantation in treating thalassemia and related disorders.
Conclusion
Hematopoietic stem cell transplantation is the only definitive curative therapy for thalassemia and has shown improved outcomes over the years.
Supporting Evidence
- Over 1000 patients underwent transplantation in Pesaro between 1981 and 2003.
- Probability of overall survival and thalassemia-free survival is 97% and 89% for patients with no advanced disease.
- Transplantation technologies have improved significantly since the 1980s.
Takeaway
Doctors can help kids with thalassemia by giving them new blood cells from a donor, which can make them healthy again.
Methodology
The study reviews historical data and outcomes of over 1000 patients who underwent transplantation for thalassemia.
Limitations
The study highlights the disparity in treatment availability between industrialized and non-industrialized countries.
Participant Demographics
Patients aged from 1 to 35 years, with a focus on those with thalassemia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website